Navigation Links
Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma
Date:6/18/2013

LONDON, June 18, 2013 /PRNewswire/ --

Edison Investment Research, a leading international investment research firm, announces the initiation of full coverage of BioAlliance Pharma (BIO.PA), a French biopharmaceutical company developing and marketing products for orphan oncology and oncology supportive care indications.

     (Logo: http://photos.prnewswire.com/prnh/20130417/608168)

Edison has today published a comprehensive report examining the investment merits of BioAlliance Pharma, focusing in particular on the potential of its lead product, Livatag, for hepatocellular carcinoma. Livatag is in a Phase III study, RELIVE, which is expected to render final results in 2016. The report identifies a number of earlier catalysts, including the potential partnering of Sitavig for cold sores, which was approved by the FDA in April 2013. Edison has valued BioAlliance at €109m based on a risk-adjusted net present value model.

For the full report see: http://www.edisoninvestmentresearch.com/research/company/bioalliance-pharma

The launch of coverage on BioAlliance is part of a programme of research initiations on healthcare companies worldwide. Edison provides research coverage on more than 130 healthcare companies in Europe, North America and Australia. Edison has pioneered a scientific, detail-oriented approach to analysing companies in the healthcare sector that is delivered in a concise and non-promotional manner. It aims to inform investors, while providing a realistic assessment of the competitive strengths and threats to key drug development programmes. All facts are carefully sourced and the analysis is underpinned by comprehensive and rigorous financial models. Edison's reports provide an overall company valuation without any specific stock recommendation.

All reports published by Edison are available to download free of charge from its website http://www.edisongroup.com.

About Edison Investment Research

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Berlin, Sydney and Wellington. Edison is authorised and regulated by the Financial Services Authority (http://www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

About BioAlliance Pharma

Dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products, BioAlliance conceives and develops innovative products for speciality markets, especially in the hospital setting and for orphan or rare diseases. Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation with patient needs. The company's teams have the key competencies required to identify, develop and register drugs in Europe and the USA.

For more information please contact:
Luke Polonieki    
Edison Investment Research          
+44-(0)-20-3077-5700
healthcare@edisongroup.com


'/>"/>
SOURCE Edison Investment Research and BioAlliance Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. CellHealth Institute is Named 2013 Edison Award Winner
2. Stanford scientists spark new interest in the century-old Edison battery
3. Cellular Dynamics International Expands MyCell Products Line with Disease Models, Genetic Engineering Patents
4. Julabo USA Inc. Expands Its Line of Compact and Economic Cooling Circulators
5. Rocky Mountain Biologicals Expands Custom Serum Filtration Facility
6. GenoSpace Expands Its Management Team by Appointing Daniel Meyer as Chief Financial Officer
7. GLM Displays Expands Its Line of Formulate Fabric Displays with the Vibe 10ft Display
8. Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
9. Leading Chemical Manufacturer Expands Biobased Offering through Unique Distribution of Proven Green Spill Absorbent
10. Defying Industry Trends, BBK Worldwide Expands Ownership From Within
11. Abacus International Expands Annual Partnership With HealthEconomics.Com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... ... 15, 2017 , ... Kenall, a leader in sealed solid-state ... tightly sealed and perform efficiently for years. The downlights are ideal for a ... enough, such as: hospitals; behavioral health facilities; cleanrooms; containment areas; food and pharmaceutical ...
(Date:8/15/2017)... Ca (PRWEB) , ... August 15, 2017 , ... ... production and is threatened by various biotic and abiotic factors. During this educational ... evolutionary history of coffee, as well as gain a better understanding of how ...
(Date:8/14/2017)... ... August 14, 2017 , ... ... antibodies. Key researchers in the antibody community have recently come together to address ... antibodies in the laboratory. , The team at Thermo Fisher ...
(Date:8/14/2017)... ... ... The Conference Forum has confirmed the one-day agenda for the ... 2017 at the Marriott Copley Place in Boston, MA. , Returning as program chair ... Pfizer Innovative Research Lab, Pfizer, who leads 19 industry speakers in discussing how and ...
Breaking Biology Technology:
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
(Date:3/24/2017)... , March 24, 2017 The Controller General ... Controller Mr. Abdulla Algeen have received the prestigious international IAIR ... Continue Reading ... ... picture) and Deputy Controller Abdulla Algeen (small picture on the right) have ...
Breaking Biology News(10 mins):